Although the recently developed DDR inhibitors such as the PARP inhibitor Talazoparib have shown promising activity as monotherapies when tested on SCLC models [86], combining these agents with cytotoxic chemotherapies, other DDR targeting agents [6], or with immunotherapy is expected to have greater clinical responses as this may increase the number of patients responding as well as the duration of the response [87]. The gene discussed is PARP1; the disease is small cell lung carcinoma.